Pricing Availability   Qty
Cat.No. 1461 - Linomide | C18H16N2O3 | CAS No. 84088-42-6
Description: Immunomodulator with antiangiogenic properties
Chemical Name: 1,2-Dihydro-4-hydroxy-N,N-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide
Purity: ≥99% (HPLC)
Literature (2)

Biological Activity

Immunomodulator with stimulatory and antitumor properties. Inhibits in vivo apoptosis of T cells and inhibits angiogenesis in rats in vivo.

Technical Data

M. Wt 308.33
Formula C18H16N2O3
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 84088-42-6
PubChem ID 54676478
Smiles CN(C(=O)C1=C(O)C2=CC=CC=C2N(C)C1=O)C1=CC=CC=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
1.1eq. NaOH 30.83 100

Preparing Stock Solutions

The following data is based on the product molecular weight 308.33. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.24 mL 16.22 mL 32.43 mL
5 mM 0.65 mL 3.24 mL 6.49 mL
10 mM 0.32 mL 1.62 mL 3.24 mL
50 mM 0.06 mL 0.32 mL 0.65 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.


References are publications that support the biological activity of the product.

Gonzalo et al (1994) Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur.J.Immunol. 24 48 PMID: 8020570

Ichikawa et al (1992) The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res. 52 3022 PMID: 1591718

Vukanovic et al (1993) Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res. 53 1833 PMID: 7682157

If you know of a relevant reference for Linomide, please let us know.

View Related Products by Target

Keywords: Linomide, Linomide supplier, Immunomodulators, antiangiogenics, Antiangiogenics, 1461, Tocris Bioscience

Citations for Linomide

Citations are publications that use Tocris products.

Currently there are no citations for Linomide. Do you know of a great paper that uses Linomide from Tocris? Please let us know.

Reviews for Linomide

There are currently no reviews for this product. Be the first to review Linomide and earn rewards!

Have you used Linomide?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Angiogenesis in Cancer

Angiogenesis in Cancer Poster

Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.